What Causes Heart Disease? Inflammation, Insulin Resistance, and Metabolism

Key Takeaways:

  • The three components of Metabolic Engineering® — the Zone Diet, omega-3 fatty acids, and polyphenols — target these underlying metabolic drivers.
  • Cardiovascular disease is strongly linked to chronic low-level inflammation in the arteries.
  • Insulin resistance and oxidative stress contribute to the development of atherosclerosis.
  • The metabolic regulator AMPK helps control cholesterol synthesis, inflammation, and cellular stress.

What Causes Heart Disease?

Cardiovascular disease is increasingly understood as a condition driven by chronic low-level inflammation within the arterial walls (1, 2).

Over time, inflammation in the arterial wall contributes to the formation of atherosclerotic plaques. These plaques can eventually rupture, damaging the blood vessel and impairing the body’s ability to repair cardiovascular tissue efficiently.

One of the major drivers of this inflammatory process is a pro-inflammatory diet, which disrupts metabolic balance and promotes:

  • Increased inflammation
  • Greater oxidative stress
  • Rising insulin resistance

These metabolic disturbances create the conditions that allow cardiovascular disease to develop and progress.

The Traditional Medical Approach to Heart Disease

Modern medical treatment for cardiovascular disease primarily focuses on cholesterol-lowering medications, especially statins.

Statins are known to activate AMPK (AMP-activated protein kinase), a key metabolic regulator that also reduces cholesterol synthesis in the liver (3, 4). In this sense, statins can be viewed as AMPK-activating drugs.

However, cholesterol alone does not explain cardiovascular risk. Research also shows that heart disease is associated with:

  • Elevated oxidative stress (5)
  • Increased insulin resistance (6)

These factors contribute to inflammation and damage within the cardiovascular system.

The Metabolic Engineering® Approach to Heart Health

Metabolic Engineering® addresses the underlying metabolic drivers of cardiovascular disease, rather than focusing on a single pathway.

This approach targets inflammation, oxidative stress, and insulin resistance through three nutritional components:

1. The Zone Diet

The dietary component of Metabolic Engineering® activates AMPK, partly due to mild calorie restriction (7). Increased AMPK activity helps regulate metabolism and reduce inflammatory signaling.

2. Omega-3 Fatty Acids

Omega-3 fatty acids help reduce inflammation and promote its resolution, an important step in preventing vascular damage (8).

3. Polyphenols

Polyphenols help reduce oxidative stress, which is strongly associated with atherosclerosis and cardiovascular disease (5).

How AMPK Supports Cardiovascular Health

When AMPK activity increases, several beneficial metabolic changes occur:

  • Decreased cholesterol synthesis
  • Reduced inflammation
  • Improved resolution of inflammatory responses
  • Lower oxidative stress through increased Nrf2 activity
  • Reduced insulin resistance
  • Decreased accumulation of senescent (aging) cells

These metabolic improvements help restore balance within the cardiovascular system.

Metabolic Engineering® and Cardiovascular Drug Therapy

Metabolic Engineering® is designed to work alongside conventional medical treatment.

By improving metabolic control through AMPK activation, this nutritional approach may help:

  • Improve the effectiveness of cardiovascular medications
  • Reduce inflammation and oxidative stress
  • Support better metabolic function overall

In some cases, improved metabolic balance may allow physicians to manage cardiovascular disease with lower drug doses and fewer side effects, while maintaining effective treatment.

References
1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105(9):1135-43. doi: 10.1161/hc0902.104353.

2. Soehnlein O and Libby P. Targeting inflammation in atherosclerosis – from experimental insights to the clinic.  Nat Rev Drug Discov. 2021; 20:589-610.doi: 10.1038/s41573-021-00198-1.

3. Dehnavi S, Kiani A, Sadeghi M, Biregani AF, Banach M, Atkin SL, Jamialahmadi T, Sahebkar A. Targeting AMPK by Statins: A potential therapeutic approach.Drugs. 2021; 81:923-933. doi: 10.1007/s40265-021-01510-4.\

4. Foretz M, Viollet B. Measurement of AMPK-induced inhibition of lipid synthesis flux in cultured cells. Methods Mol Biol. 2018; 1732:363-371. doi: 10.1007/978-1-4939-7598-3_23.

5. Cheng YC, Sheen JM, Hu WL, Hung YC.  Polyphenols and oxidative stress in atherosclerosis-related ischemic heart disease and stroke.  Oxid Med Cell Longev. 2017; 2017:8526438. doi: 10.1155/2017/8526438. 

6. Kosmas CE, Bousvarou MD, Kostara CE, Papakonstantinou EJ, Salamou E, Guzman E.  Insulin resistance and cardiovascular disease.   J Int Med Res. 2023; 51: 3000605231164548. doi: 10.1177/03000605231164548.

7. Guo Z, Wang M, Ying X, Yuan J, Wang C, Zhang W, Tian S, Yan X. Caloric restriction increases the resistance of aged heart to myocardial ischemia/reperfusion injury via modulating AMPK-SIRT1-PGC1a energy metabolism pathway.  Sci Rep. 2023, 13:2045. doi: 10.1038/s41598-023-27611-6.

8. Back M, and Hansson GK. Omega-3 fatty acids, cardiovascular risk, and the resolution of inflammation. FASEB J. 2019; 33:1536-1539. doi: 10.1096/fj.201802445R.

For more content on heart disease, click here